
News|Articles|December 11, 2014
The Need to Study Tissue Biomarkers
Author(s)David L. Rimm MD, PhD
David L. Rimm MD, PhD, from Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
Advertisement
Clinical Pearls
David L. Rimm MD, PhD, Professor of Pathology and of Medicine (Medical Oncology), Director of Pathology Tissue Services, Director of Translational Pathology, Yale School of Medicine, discusses the need for further research into tissue biomarkers in breast cancer.
- Tissue biomarkers may help to determine which patients will respond to certain drugs.
- Biologically, cancers are different. It is important to be able to determine how patients will respond to treatment.
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















